HPV Vaccines
Wendy Landier, PhD, CRNP, FAAN, serves as Associate Professor, School of Nursing Associate Director, Institute for Cancer Outcomes and Survivorship for UAB. Dr. Landier's practice at Children's of Alabama is in the Hematology/Oncology Division.
Dr. Landier has provided two studies about the HPV vaccine in cancer survivors. The first study showed that HPV vaccination rates in cancer survivors are significantly lower than those in the healthy age-matched population. The primary reason for that is lack of healthcare provider recommendation for the vaccine.
Dr. Landier also tested the HPV vaccine in survivors and found that the 3-dose HPV vaccine series is safe and has a similar immunogenicity profile to that seen in the age-matched general population.
The second study, currently in progress, is testing the effectiveness and evaluating the implementation of a healthcare provider-directed intervention known as “HPV PROTECT” in increasing HPV vaccination rates in cancer survivors.